Science Pool

Investigating Rosuvastatin DDI Prediction

Rosuvastatin is used in the treatment of dyslipidemia. The drug transporter BCRP (breast cancer resistant protein) has been identified as the rate limiting barrier to rosuvastatin absorption.

In this poster, we focus on:

  • whether estrone 3-sulfate can be applied as a surrogate in vitro BCRP probe substrate for predicting rosuvastatin DDI 
  • a comparison of BCRP inhibition assessment using rosuvastatin or estrone 3-sulfate as probe substrate for six established BCRP inhibitors for which a clinical DDI with rosuvastatin has been characterised

Read our poster to learn more about our research!

Sounds interesting?
Enter your details below to continue reading…

By clicking on ‘Continue’ I agree that my data is being transferred to the Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our Privacy Policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Join our community

Discover the exclusive benefits on offer if you join our community.